These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 25047874

  • 1. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 3. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, Kuppermann BD.
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [Abstract] [Full Text] [Related]

  • 4. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A, Grotelüschen S, Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [Abstract] [Full Text] [Related]

  • 5. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [Abstract] [Full Text] [Related]

  • 6. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L, Fuhrer R, Zinkernagel M, Enzmann V.
    Ophthalmologica; 2019 Oct; 241(3):137-142. PubMed ID: 30001546
    [Abstract] [Full Text] [Related]

  • 7. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [Abstract] [Full Text] [Related]

  • 8. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB, Rho CR, Shin JA, Lyu J, Kang S.
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [Abstract] [Full Text] [Related]

  • 9. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.
    Cell Physiol Biochem; 2016 Aug; 38(2):737-47. PubMed ID: 26871551
    [Abstract] [Full Text] [Related]

  • 10. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [Abstract] [Full Text] [Related]

  • 11. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H, Nomura Y, Nishida J, Fujino Y, Yanagi Y, Kawashima H.
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [Abstract] [Full Text] [Related]

  • 12. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Eur J Ophthalmol; 2016 Aug 04; 26(5):425-30. PubMed ID: 27079208
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA, Abedi S, Schneider K, Chwa M, Kenney MC.
    Exp Eye Res; 2018 Dec 04; 177():112-116. PubMed ID: 30071215
    [Abstract] [Full Text] [Related]

  • 15. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S, Biesemeier A, Taubitz T, Schraermeyer U.
    Br J Ophthalmol; 2014 Jun 04; 98(6):813-25. PubMed ID: 24457369
    [Abstract] [Full Text] [Related]

  • 16. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S.
    Biochem Pharmacol; 2015 Aug 01; 96(3):278-87. PubMed ID: 26056075
    [Abstract] [Full Text] [Related]

  • 17. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L, Roider J, Klettner A.
    Ophthalmic Res; 2021 Aug 01; 64(3):369-388. PubMed ID: 33011724
    [Abstract] [Full Text] [Related]

  • 18. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL, Lang GK, Lang GE.
    Exp Eye Res; 2014 May 01; 122():20-31. PubMed ID: 24631334
    [Abstract] [Full Text] [Related]

  • 19. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E, Ayaz L, Kurt AH.
    J Ocul Pharmacol Ther; 2018 May 01; 34(4):346-353. PubMed ID: 29389239
    [Abstract] [Full Text] [Related]

  • 20. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, Aisenbrey S.
    Br J Ophthalmol; 2013 Jul 01; 97(7):917-23. PubMed ID: 23686000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.